Helen Torley, who serves as President and Chief Executive Officer of Halozyme Therapeutics, INC. (NASDAQ: HALO), disposed of 10,000 shares of the company's common stock on April 6, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The sale was executed under a pre-established 10b5-1 trading arrangement and generated total proceeds of $634,981. The filing reports that the shares sold fell within a price range of $63.139 to $64.015. More granularly, the disclosure shows 5,900 shares transacted at a weighted-average price of $63.139 and the remaining 4,100 shares at a weighted-average price of $64.015.
On the same date, Ms. Torley exercised options to buy 10,000 shares of Halozyme common stock at an exercise price of $12.07, producing an aggregate exercise value of $120,700. Those options originated from a grant dated February 22, 2017, and the filing notes they are exercisable over a four-year schedule consistent with the grant terms.
Following the April 6 transactions, Ms. Torley is reported to directly hold 767,780 shares of Halozyme common stock. In addition to her shareholdings, she retains 101,923 outstanding options to purchase common stock.
Market quotations included in the filing place Halozyme's current trading price at $63.60 per share, corresponding to a market capitalization of $7.53 billion. Independent analysis cited in the filing, provided by InvestingPro, indicates that Halozyme is trading below its Fair Value estimate and characterizes the company as undervalued at prevailing levels. InvestingPro's assessment also assigns Halozyme a "GREAT" financial health score, a conclusion supported in part by reported revenue growth of 38% over the last twelve months.
For subscribers, InvestingPro provides additional commentary and proprietary content on HALO, noting more than 10 exclusive tips that touch on topics such as the company's aggressive share buyback program and its profitability trajectory. The platform also offers an extended Pro Research Report on Halozyme, one of over 1,400 U.S. equities covered in its research universe.
The filing and supplementary materials reiterate results disclosed in the company's recent financial update. Halozyme reported fourth quarter 2025 revenue of $451.8 million, a 52% increase year-over-year. Despite that top-line expansion, the company recorded a non-GAAP diluted loss per share of $0.24. The company attributes that loss in part to $2.42 per share in acquisition-related write-offs, which materially affected the adjusted earnings metric.
Following the results, Benchmark increased its price target on Halozyme to $90 and maintained a Buy rating. Separately, Leerink Partners reiterated a Market Perform rating and set a price target of $83, a stance taken in the context of Halozyme's strategic moves including a collaboration and license agreement with Vertex Pharmaceuticals.
Under that transaction, Vertex received rights to use Halozyme's Hypercon technology for as many as three drug targets, a collaboration described in the disclosure. The company also announced an internal leadership change, naming David Ramsay as Interim Chief Financial Officer effective March 23. Ramsay has previously served as Halozyme's CFO in two prior terms.
Finally, the filing references a regulatory milestone noted by the company: the U.S. Food and Drug Administration approved Johnson & Johnson's TECVAYLI in combination with DARZALEX FASPRO for multiple myeloma, an event Halozyme highlighted in its statements.
The set of insider transactions - comprising both a stock sale under a 10b5-1 plan and a simultaneous option exercise - is presented in the public filing alongside recent corporate performance metrics, analyst commentary, strategic partnerships and executive changes. The document provides shareholders and market participants with a consolidated view of ownership changes, recent operating results and near-term strategic positioning.